Login to Your Account

Other News To Note

Wednesday, October 17, 2012
• BioLineRx Ltd., of Jerusalem, said it successfully completed the preclinical development of BL-8020, an orally available, interferon-free treatment for the hepatitis C virus and plans to start a Phase I/II safety and efficacy study for the compound in Europe during the first quarter of 2013.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription